| Drug General Information |
| Drug ID |
D0U4TY
|
| Former ID |
DNC010609
|
| Drug Name |
4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H21N3
|
| Canonical SMILES |
CCCC1=NC(=NC(=C1)C2CCCCCC2)C#N
|
| InChI |
1S/C15H21N3/c1-2-7-13-10-14(18-15(11-16)17-13)12-8-5-3-4-6-9-12/h10,12H,2-9H2,1H3
|
| InChIKey |
UOAUUFFKQMFGTJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cathepsin S |
Target Info |
Inhibitor |
[1]
|
|---|
| Cathepsin K |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Lysosome
|
|
Phagosome
|
|
Antigen processing and presentation
|
|
Tuberculosishsa04142:Lysosome
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
IL2 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Reactome
|
Endosomal/Vacuolar pathway
|
|
Degradation of the extracellular matrix
|
|
Trafficking and processing of endosomal TLR
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
MHC class II antigen presentationR-HSA-1442490:Collagen degradation
|
|
Activation of Matrix Metalloproteinases
|
|
MHC class II antigen presentation
|
|
WikiPathways
|
Class I MHC mediated antigen processing & presentation
|
|
Trafficking and processing of endosomal TLRWP2018:RANKL/RANK Signaling Pathway
|
|
Osteoclast Signaling
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. Epub 2010 Jan 25.Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. |
|---|
